{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464199643
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = scFv
| source = zu/o
| target = [[Complement component 5]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status = investigational
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number =  
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = CHZ6OLQ3UU
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D10023
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Pexelizumab''' is a [[pharmaceutical drug|drug]] designed to reduce side effects of [[coronary artery bypass grafting]]<ref>[http://www.clinicaltrials.gov/ct2/show/NCT00088179 ClinicalTrials.gov:] Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass</ref> and [[angioplasty]],<ref>[http://www.clinicaltrials.gov/ct2/show/NCT00091637 ClinicalTrials.gov:] Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction</ref><ref>{{cite journal|pmid=18954626|year=2008|last1=Testa|first1=L|last2=Van Gaal|last3=Bhindi|last4=Biondi-Zoccai|last5=Abbate|last6=Agostoni|last7=Porto|last8=Andreotti|last9=Crea|title=Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients|volume=136|issue=4|pages=884–93|doi=10.1016/j.jtcvs.2007.12.062|journal=The Journal of thoracic and cardiovascular surgery|first2=WJ|first3=R|first4=GG|first5=A|first6=P|first7=I|first8=F|first9=F|last10=Banning|first10=A.P.|display-authors=8}}</ref> among other types of [[cardiac surgery]]. It is a [[single chain variable fragment]] of a [[monoclonal antibody]] targeted against [[Complement component 5|component 5]] of the [[complement system]].<ref>{{cite journal|pmid=15331798|year=2004|last1=Mathew|first1=JP|last2=Shernan|first2=SK|last3=White|first3=WD|last4=Fitch|first4=JC|last5=Chen|first5=JC|last6=Bell|first6=L|last7=Newman|first7=MF|title=Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery.|volume=35|issue=10|pages=2335–9|doi=10.1161/01.STR.0000141938.00524.83|journal=Stroke; a journal of cerebral circulation}}</ref>

== Current status ==

Alexion, the developer of pexelizumab, stopped development when the phase 3 trial indicated the heart-attack drug is no better than placebo.<ref>[http://www.upi.com/Health_News/2007/01/02/Analysis-Alexions-pexelizumab-fails/UPI-61131167778114/] Analysis: Alexion's pexelizumab fails</ref>

==References==
{{reflist}}

{{immunosuppressants}}
{{Monoclonals for immune system}}

[[Category:Monoclonal antibodies]]
[[Category:Experimental drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}